ABPI 150

Drug Profile

ABPI 150

Alternative Names: ABP 150

Latest Information Update: 14 Mar 2007

Price : $50

At a glance

  • Originator Apollo BioPharmaceutics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Parkinson's disease

Most Recent Events

  • 07 Sep 2006 Discontinued - Phase-I for Parkinson's disease in USA (unspecified route)
  • 07 Sep 2004 No development reported - Phase-I for Parkinson's disease in USA (unspecified route)
  • 10 Sep 2001 Phase-I clinical trials for Parkinson's disease in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top